| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | serine threonine kinase 3/4; KRS1; MST2/KRS2; MST1; YSK3; TIIAC |
| Entrez GeneID | 6789 |
| WB Predicted band size | Calculated MW: 56 kDa; Observed MW: 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human Serine/threonine-protein kinase 4 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于MSP抗体(以疟原虫裂殖子表面蛋白为例)的3篇代表性文献摘要及作者信息：
1. **"Antibodies against Plasmodium falciparum malaria at the molecular level"**
- **作者**: Miller LH, et al.
- **摘要**: 研究聚焦恶性疟原虫MSP1抗体的作用，揭示其通过阻断裂殖子入侵红细胞抑制疟疾发展，为疫苗设计提供靶点依据。
2. **"Naturally acquired antibodies to Plasmodium falciparum merozoite surface protein 3: prevalence and protective immunity"**
- **作者**: Osier FHA, et al.
- **摘要**: 分析非洲儿童体内自然获得的MSP3抗体水平，发现高抗体滴度与降低重症疟疾风险相关，支持MSP3作为疫苗候选分子。
3. **"Structural basis for recognition of Plasmodium falciparum MSPDBL双功能蛋白 by protective antibodies"**
- **作者**: Singh SK, et al.
- **摘要**: 通过冷冻电镜解析MSPDBL蛋白与中和抗体的复合物结构，阐明抗体通过靶向关键表位阻断疟原虫生命周期。
*注：MSP抗体研究多聚焦疟疾，若需其他领域(如多发性硬化症相关MSP)，请补充说明调整方向。*
MSP (Merozoite Surface Protein) antibodies are critical components in the immune response against malaria, particularly caused by *Plasmodium falciparum*. MSPs, such as MSP1. MSP2. and MSP3. are proteins expressed on the surface of the merozoite stage of the parasite, which invades human red blood cells. During infection, these proteins play essential roles in erythrocyte recognition, adhesion, and invasion. Antibodies targeting MSPs aim to block these processes, neutralizing merozoites and limiting parasite replication.
MSP1. the most studied, undergoes proteolytic processing during invasion; its C-terminal fragment (MSP1-19) is a focus of vaccine development. Naturally acquired MSP antibodies are associated with partial immunity in endemic regions, though protection is strain-specific due to antigenic diversity. Vaccine trials, like the MSP3-based candidate, showed limited efficacy, highlighting challenges in eliciting broadly neutralizing responses.
Research also explores MSP antibodies as biomarkers of exposure and immune status. However, their role in immunity is complex, involving both humoral and cellular responses. While MSP-based vaccines remain promising, overcoming antigenic variation and enhancing durable antibody responses are key hurdles. Understanding MSP antibody dynamics continues to inform malaria vaccine design and serological surveillance strategies.
×
